A bombshell Cochrane review questions the effectiveness of anti-amyloid Alzheimer’s drugs like Leqembi and Kisunla, calling their benefits “absent or trivial” despite FDA approvals. Cochrane Analysis: Little to No Clinical Benefit The
A bombshell Cochrane review questions the effectiveness of anti-amyloid Alzheimer’s drugs like Leqembi and Kisunla, calling their benefits “absent or trivial” despite FDA approvals. Cochrane Analysis: Little to No Clinical Benefit The